Remdesivir News and Research

RSS

New book gives overview of viruses and how they emerge to cause pandemics

Since the novel coronavirus SARS-Cov-2 emerged late last year, it has been virtually impossible to consume any news without encountering stories about the virus and how it spreads, potential treatments, and the development of new vaccines.

11 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Health officials worry nation is not ready for COVID-19 vaccine

Millions of Americans are counting on a COVID-19 vaccine to curb the global pandemic and return life to normal.

2 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Cat antiviral that inhibits SARS-CoV-2 fast-tracked for human clinical trials

Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.

31 Aug 2020

New lipid derivatives of Remdesivir have higher anti-coronavirus activity

In a fascinating new preprint paper published on bioRxiv* in August 2020, the researchers report “the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in cells infected with SARS-CoV-2.” These could be of immense use in treating COVID-19 patients early and helping to end transmission.

30 Aug 2020

Scientists describe known approaches for treatment of SARS-CoV-2 infection

Researchers from Sechenov University together with Russian and Iranian colleagues described currently known approaches to the treatment of SARS-CoV-2 infection.

29 Aug 2020

Mouse-adapted SARS-CoV-2 model helps advance the development of COVID-19 vaccines

A new COVID-19 mouse model developed at the University of North Carolina at Chapel Hill captures many of the features of human disease and has helped advance a COVID-19 vaccine candidate to clinical trial.

27 Aug 2020

5 things to know about convalescent blood plasma

President Donald Trump told the American people this week that convalescent plasma is a potential new treatment for COVID-19.

27 Aug 2020

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.

25 Aug 2020

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

University Hospitals announced today plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2.

24 Aug 2020

SARS-CoV-2 ORF9c responsible for immune evasion and efficient infection of host

A recent study by researchers at the Sanford Burnham Prebys Medical Discovery Institute and the University of California San Francisco and published on the preprint server bioRxiv in August 2020 shows that a protein encoded by the subgenomic sequence ORF9c of SARS-CoV-2 is responsible for the low antiviral response in infected humans, enabling the successful replication of the virus in the host.

21 Aug 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

Machine learning helps detect new potential drugs to treat COVID-19

Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

12 Aug 2020

Novel strategy provides new hope to fight COVID-19

A novel strategy has been developed by Novateur Ventures, which provides new hope in battle against COVID-19. The study titled 'A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes' was published in Frontiers in Pharmacology, a leading peer-reviewed journal.

12 Aug 2020

People of color, minority groups are underrepresented in COVID-19 clinical trials

Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials, according to a new perspective authored by faculty from the University of Georgia and University of Colorado and pharmacists from Phoebe Putney Memorial Hospital in Albany.

11 Aug 2020

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health, Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

10 Aug 2020

Study: Drinking honeysuckle decoction accelerates the negative conversion of COVID-19 patients

In a new study in Cell Discovery, Chen-Yu Zhang's group at Nanjing University and two other groups from Wuhan Institute of Virology and the Second Hospital of Nanjing present a novel finding that absorbed miRNA MIR2911 in honeysuckle decoction (HD) can directly target SARS-CoV-2 genes and inhibit viral replication. Drinking of HD accelerate the negative conversion of COVID-19 patients.

7 Aug 2020

Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19

New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.

5 Aug 2020